US Patent Issued to GUANGZHOU REFORGENE MEDICINE on Dec. 16 for "SnRNA targeting USH2A pre-mRNA and application thereof" (Chinese Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,497,617, issued on Dec. 16, was assigned to GUANGZHOU REFORGENE MEDICINE Co. LTD. (Guangzhou, China).

"SnRNA targeting USH2A pre-mRNA and application thereof" was invented by Junbin Liang (Guangdong, China), Jiayu Ou (Guangdong, China), Hui Xu (Guangdong, China) and Simiao Lin (Guangdong, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is snRNA which targets USH2A pre-mRNA. The recognition domain of the snRNA is the reverse complement of a USH2A pre-mRNA sequence. The snRNA binds to the USH2A pre-mRNA to splice and jump exon 13. The snRNA promotes a higher exon 13 skipping efficiency than AON."

The patent was filed on July 4, 2024, under ...